Bank of Hawaii Sells 1,725 Shares of IDEXX Laboratories, Inc. $IDXX

Bank of Hawaii lowered its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 53.9% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,475 shares of the company’s stock after selling 1,725 shares during the quarter. Bank of Hawaii’s holdings in IDEXX Laboratories were worth $998,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the business. Reflection Asset Management acquired a new position in IDEXX Laboratories in the 4th quarter valued at approximately $53,000. BDFS Capital LLC acquired a new stake in shares of IDEXX Laboratories during the 4th quarter worth approximately $671,000. MidFirst Bank bought a new stake in shares of IDEXX Laboratories during the fourth quarter valued at approximately $2,960,000. Pacer Advisors Inc. lifted its position in IDEXX Laboratories by 10.0% in the fourth quarter. Pacer Advisors Inc. now owns 13,965 shares of the company’s stock worth $9,448,000 after purchasing an additional 1,269 shares during the period. Finally, Titan Investment Management LLC bought a new position in IDEXX Laboratories in the fourth quarter worth $1,675,000. 87.84% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the stock. UBS Group lowered their price target on shares of IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a report on Tuesday, April 28th. Weiss Ratings downgraded shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a report on Monday, May 11th. Wall Street Zen upgraded shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a research report on Saturday, June 13th. Citigroup initiated coverage on shares of IDEXX Laboratories in a research report on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 price target for the company. Finally, Stifel Nicolaus cut their price target on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a research note on Tuesday, March 31st. Seven analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat, IDEXX Laboratories has an average rating of “Moderate Buy” and a consensus target price of $751.00.

IDEXX Laboratories Price Performance

Shares of IDXX opened at $562.09 on Friday. The business’s fifty day moving average price is $561.66 and its two-hundred day moving average price is $620.91. The firm has a market capitalization of $44.34 billion, a price-to-earnings ratio of 41.39, a PEG ratio of 3.07 and a beta of 1.55. IDEXX Laboratories, Inc. has a 52 week low of $506.91 and a 52 week high of $769.98. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.82 and a current ratio of 1.12.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.41 by $0.06. The business had revenue of $1.14 billion for the quarter, compared to analyst estimates of $1.12 billion. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The firm’s revenue for the quarter was up 14.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.91 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. On average, analysts predict that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.